$CRBP
Corbus Pharmaceuticals Holdings, Inc.

2022 Q2 Form 10-Q Financial Statement

#000095017022009050 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.840M $5.231M $4.235M
YoY Change -13.14% -2.04% -20.99%
% of Gross Profit
Research & Development $2.500M $3.286M $5.764M
YoY Change -77.81% -69.35% -64.22%
% of Gross Profit
Depreciation & Amortization $192.1K $195.7K $207.7K
YoY Change -27.75% -28.09% -25.83%
% of Gross Profit
Operating Expenses $7.340M $8.517M $9.998M
YoY Change -56.41% -46.97% -53.43%
Operating Profit -$12.34M -$8.517M
YoY Change -44.74%
Interest Expense -$700.2K -$726.7K -$372.0K
YoY Change 233.89% 13.55% -65.23%
% of Operating Profit
Other Income/Expense, Net -$208.7K -$920.1K $109.7K
YoY Change -8.32% 41.34% -99.17%
Pretax Income -$13.25M -$9.437M -$10.26M
YoY Change -22.69% -41.27% 19.17%
Income Tax
% Of Pretax Income
Net Earnings -$13.25M -$9.437M -$10.26M
YoY Change -22.69% -41.26% 19.17%
Net Earnings / Revenue
Basic Earnings Per Share -$3.18 -$0.08
Diluted Earnings Per Share -$105.8K -$75.35K -$81.92K
COMMON SHARES
Basic Shares Outstanding 125.3M 125.2M 125.2M
Diluted Shares Outstanding 4.170M 4.170M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.30M $86.12M $97.65M
YoY Change -31.14% -30.55% 14.34%
Cash & Equivalents $21.78M $57.03M $25.01M
Short-Term Investments $47.53M $29.09M $72.64M
Other Short-Term Assets $1.935M $2.354M $2.557M
YoY Change -29.01% -42.58% -37.62%
Inventory
Prepaid Expenses $1.094M
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $75.24M $88.48M $100.2M
YoY Change -32.57% -32.1% 8.83%
LONG-TERM ASSETS
Property, Plant & Equipment $6.247M $2.210M $2.393M
YoY Change -26.13% -75.16% -41.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $581.6K $75.28K $46.39K
YoY Change 1.59% -92.47% -80.18%
Total Long-Term Assets $6.829M $7.200M $7.526M
YoY Change -24.37% -26.54% -26.37%
TOTAL ASSETS
Total Short-Term Assets $75.24M $88.48M $100.2M
Total Long-Term Assets $6.829M $7.200M $7.526M
Total Assets $82.07M $95.68M $107.7M
YoY Change -31.96% -31.71% 5.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.987M $2.697M $1.782M
YoY Change 5.77% -25.09% -75.85%
Accrued Expenses $5.924M $5.496M $10.09M
YoY Change -63.34% -70.76% -54.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.586M $5.178M $3.093M
YoY Change 7286.84% 1194.53% 341.91%
Total Short-Term Liabilities $15.63M $15.12M $17.01M
YoY Change -16.58% -35.94% -46.68%
LONG-TERM LIABILITIES
Long-Term Debt $11.61M $13.73M $15.64M
YoY Change -36.8% -24.57% -13.27%
Other Long-Term Liabilities $5.355M $22.21K $22.21K
YoY Change -18.12% -99.67%
Total Long-Term Liabilities $16.97M $13.75M $15.66M
YoY Change -31.9% -45.0% -13.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.63M $15.12M $17.01M
Total Long-Term Liabilities $16.97M $13.75M $15.66M
Total Liabilities $32.60M $34.52M $38.62M
YoY Change -25.32% -28.97% -32.27%
SHAREHOLDERS EQUITY
Retained Earnings -$359.2M -$349.7M
YoY Change 15.01%
Common Stock $12.53K $12.52K
YoY Change 26.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.47M $61.16M $69.11M
YoY Change
Total Liabilities & Shareholders Equity $82.07M $95.68M $107.7M
YoY Change -31.96% -31.71% 5.31%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$13.25M -$9.437M -$10.26M
YoY Change -22.69% -41.26% 19.17%
Depreciation, Depletion And Amortization $192.1K $195.7K $207.7K
YoY Change -27.75% -28.09% -25.83%
Cash From Operating Activities -$12.23M -$10.62M -$9.703M
YoY Change -30.23% -51.33% -46.78%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $13.45K -$54.17K
YoY Change -190.28%
Acquisitions
YoY Change
Other Investing Activities -$18.70M $42.98M -$3.123M
YoY Change 42.69% -174.84%
Cash From Investing Activities -$18.70M $42.96M -$3.177M
YoY Change 42.69% -174.82% -5395.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -330.1K -327.1K 767.9K
YoY Change 31.08% -100.54% -96.47%
NET CHANGE
Cash From Operating Activities -12.23M -10.62M -9.703M
Cash From Investing Activities -18.70M 42.96M -3.177M
Cash From Financing Activities -330.1K -327.1K 767.9K
Net Change In Cash -31.26M 32.02M -12.11M
YoY Change 1.21% -270.13% -440.23%
FREE CASH FLOW
Cash From Operating Activities -$12.23M -$10.62M -$9.703M
Capital Expenditures $0.00 $13.45K -$54.17K
Free Cash Flow -$12.23M -$10.63M -$9.648M
YoY Change -51.27% -47.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2021Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-37348
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001595097
CY2022Q1 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
CY2021Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-359171006
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Corbus Pharmaceuticals Holdings, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4348039
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
500 River Ridge Drive
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Norwood
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02062
CY2022Q1 dei City Area Code
CityAreaCode
(617)
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
963-0100
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
CRBP
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
125255881
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57026334
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25006632
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
29094916
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
72640520
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2161860
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2365010
CY2022Q1 us-gaap Assets Current
AssetsCurrent
88475585
CY2021Q4 us-gaap Assets Current
AssetsCurrent
100204637
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2210426
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2392696
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4436376
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4609110
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
75275
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
46385
CY2022Q1 us-gaap Assets
Assets
95675087
CY2021Q4 us-gaap Assets
Assets
107730253
CY2022Q1 us-gaap Notes Payable Current
NotesPayableCurrent
440815
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
767938
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2696810
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1782277
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5496406
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10093312
CY2022Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
133710
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
133710
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1171858
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1136948
CY2022Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
5178107
CY2021Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3093344
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15117706
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17007529
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13728413
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15636275
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22205
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22205
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5651480
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5956217
CY2022Q1 us-gaap Liabilities
Liabilities
34519804
CY2021Q4 us-gaap Liabilities
Liabilities
38622226
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125255881
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125255881
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125230881
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125230881
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
12526
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
12523
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
420483456
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
418891713
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-359171006
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-349733764
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-169693
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-62445
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
61155283
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
69108027
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95675087
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107730253
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
647824
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3286236
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10720823
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5230923
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5341197
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
8517159
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
16062020
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8517159
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15414196
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-193351
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15094
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-458909
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-646550
CY2022Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0
CY2021Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-6000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-267823
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
16672
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-920083
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-650972
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-9437242
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16065168
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
125243242
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
116344900
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9437242
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16065168
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-107248
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-28765
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-107248
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-28765
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9544490
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16093933
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
69108027
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1591746
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-107248
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9437242
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
61155283
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
45274925
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2580402
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1820437
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
58860801
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
894799
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-28765
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16065168
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
91516994
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9437242
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16065168
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1591746
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2580402
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
195719
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
272186
CY2022Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
454978
CY2021Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
901
CY2022Q1 crbp Gain Loss On Foreign Exchange Rate
GainLossOnForeignExchangeRate
-349226
CY2021Q1 crbp Gain Loss On Foreign Exchange Rate
GainLossOnForeignExchangeRate
73976
CY2022Q1 crbp Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
172734
CY2021Q1 crbp Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
152360
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
176901
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
170284
CY2022Q1 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-7752
CY2022Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0
CY2021Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-6000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5456
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-203150
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-54067
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
647824
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
28890
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
70000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
565308
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3691841
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4596906
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4262958
CY2022Q1 crbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-269826
CY2021Q1 crbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-237592
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10615350
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21809505
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6471309
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
57427043
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
49446935
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13449
CY2021Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2600
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42962177
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57424443
CY2022Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
327125
CY2021Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
301880
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62536070
CY2021Q1 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1820437
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-327125
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60413753
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32019702
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18820195
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25676532
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
86453341
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57696234
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67633146
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
430998
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
432455
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">NATURE OF OPERATIONS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Corbus Pharmaceuticals Holdings, Inc. (the “Company” or “Corbus”) is focused on the development of immune modulators that will have application in disease states spanning from immuno-oncology to fibrosis. Corbus’ current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. The Company plans to expand its pipeline in immuno-oncology through internal efforts and business development. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve profitability.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation. In the opinion of management of the Company, the accompanying unaudited condensed consolidated interim financial statements reflect all adjustments (which include only normal recurring adjustments) necessary to present fairly, in all material respects, the consolidated financial position of the Company as of March 31, 2022 and the results of its operations and changes in stockholders’ equity for the three months ended March 31, 2022 and 2021 and its cash flows for the three months ended March 31, 2022 and 2021. The December 31, 2021 condensed consolidated balance sheet was derived from audited financial statements. The Company prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (the “SEC”) for interim reporting. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP) have been condensed or omitted. It is suggested that these condensed consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 8, 2022 (the “2021 Annual Report”). The results of operations for such interim periods are not necessarily indicative of the operating results for the full fiscal year.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is continuing to monitor the impact of the COVID-19 pandemic on its business and operations.</span></p>
CY2022Q1 crbp Cash And Cash Equivalents And Marketable Debt Securities
CashAndCashEquivalentsAndMarketableDebtSecurities
86121000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25676532
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock-based compensation, the accrual of research, product development and clinical obligations, and the valuation of warrants discussed in Note 14.</span></p>
CY2022Q1 us-gaap Cash
Cash
12942128
CY2021Q4 us-gaap Cash
Cash
6751593
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
44084206
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18255039
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57026334
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25006632
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
669900
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
669900
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57696234
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits. However, the Company believes the risk of loss is minimal as these banks are large financial institutions.</span></p>
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
606000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
14478000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9437242
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16065168
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125243242
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116344900
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2022Q1 crbp Available For Sale Other Investments And Debt Securities Amortized Cost Basis
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis
29264000
CY2022Q1 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-0
CY2022Q1 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
169000
CY2022Q1 crbp Available For Sale Securities Other Investments And Debt Securities
AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities
29095000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
14598000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
4666000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
4617000
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
19264000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
19095000
CY2021Q4 crbp Available For Sale Other Investments And Debt Securities Amortized Cost Basis
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis
72703000
CY2021Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-62000
CY2021Q4 crbp Available For Sale Securities Other Investments And Debt Securities
AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities
72641000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
44859000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
44847000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
11092000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
11041000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
55951000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
55888000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4778387
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4764938
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2567961
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2372242
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2210426
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2392696
CY2022Q1 us-gaap Depreciation
Depreciation
195719
CY2021Q1 us-gaap Depreciation
Depreciation
272186
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1245353
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1700005
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1747447
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1794889
CY2022Q1 crbp Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1688145
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8175839
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1352501
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
6823338
CY2022Q1 crbp Sublease Agreement Description
SubleaseAgreementDescription
Effective August 26, 2021, the Company entered into a sublease agreement with a third party to sublease 12,112 square feet of the 30,023 square feet currently being leased under one of its two existing lease agreements. The sublease commenced on October 1, 2021 and ends October 31, 2026. The Company notes sublease income of $55,133 and $0 was recognized and offset against rent expense for the three months ended March 31, 2022 and 2021, respectively.
CY2021Q3 crbp Sublease Area
SubleaseArea
12112
CY2021Q3 crbp Sublease Area Total
SubleaseAreaTotal
30023
CY2022Q1 crbp Subleases Income
SubleasesIncome
55133
CY2021Q1 crbp Subleases Income
SubleasesIncome
0
CY2022Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
78728
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
185717
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
278576
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
290688
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
252333
CY2022Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1086042
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1093750
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
684000
CY2021Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
658000
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2262388
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1549871
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2715368
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2262388
CY2022Q1 crbp Accretion Of Debt Discount
AccretionOfDebtDiscount
1168908
CY2021Q4 crbp Accretion Of Debt Discount
AccretionOfDebtDiscount
992007
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18906520
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18729619
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
5178107
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3093344
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13728413
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15636275
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3086443
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
9830223
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
8273334
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
21190000
CY2022Q1 crbp Accrued Clinical Operations And Trials Costs Current
AccruedClinicalOperationsAndTrialsCostsCurrent
2132865
CY2021Q4 crbp Accrued Clinical Operations And Trials Costs Current
AccruedClinicalOperationsAndTrialsCostsCurrent
5435464
CY2022Q1 crbp Accrued Product Development Costs Current
AccruedProductDevelopmentCostsCurrent
7788
CY2021Q4 crbp Accrued Product Development Costs Current
AccruedProductDevelopmentCostsCurrent
203676
CY2022Q1 crbp Accrued Administrative Costs
AccruedAdministrativeCosts
1198396
CY2021Q4 crbp Accrued Administrative Costs
AccruedAdministrativeCosts
1213699
CY2022Q1 us-gaap Interest Payable Current
InterestPayableCurrent
607486
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4636015
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.47
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
417505
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.78
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
525105
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5496406
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10093312
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125255881
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125255881
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125230881
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125230881
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1591746
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2580402
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1591746
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2580402
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15326105
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.06
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
277925
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.75
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19266690
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.17
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M7D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10371031
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
9906454
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.57
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y4M24D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
2635020
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
17633030
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.36
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y25D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8581750
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.37
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.09
CY2021Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
133710
CY2022Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0
CY2022Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
133710

Files In Submission

Name View Source Status
0000950170-22-009050-index-headers.html Edgar Link pending
0000950170-22-009050-index.html Edgar Link pending
0000950170-22-009050.txt Edgar Link pending
0000950170-22-009050-xbrl.zip Edgar Link pending
crbp-20220331.htm Edgar Link pending
crbp-20220331.xsd Edgar Link pending
crbp-20220331_cal.xml Edgar Link unprocessable
crbp-20220331_def.xml Edgar Link unprocessable
crbp-20220331_htm.xml Edgar Link completed
crbp-20220331_lab.xml Edgar Link unprocessable
crbp-20220331_pre.xml Edgar Link unprocessable
crbp-ex31_1.htm Edgar Link pending
crbp-ex31_2.htm Edgar Link pending
crbp-ex32_1.htm Edgar Link pending
crbp-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending